ADAMTS13 and hyperinsulinemic hypoglycemia, familial, 4: The PLASMIC score is used to stratify patients with TMA according to their risk of severe ADAMTS13 deficiency based on the following seven items: platelet count <30 × 109/L, hemolysis variable (elevated reticulocyte count, undetectable haptoglobin, or indirect bilirubin >2.0 mg/dL), no active cancer, no history of solid organ or stem cell transplant, mean corpuscular volume (MCV) <90 fL, international normalized ratio (INR) <1.5, and creatinine <2.0 mg/dL (7, 12, 13).